
Regeneron's Livsayis (cemdisiran) gains FDA approval for adults with antibody-positive generalized myasthenia gravis, dosed four times a year.
Rules imposed by FDA and other regulatory agencies add legal challenges to promoting pharmaceuticals.
over 25 years ago
The Power of Public Relationsover 25 years ago
Market Research 101over 25 years ago
World-Class Marketing Plansover 25 years ago
How to Win Friends and Influence R&Dover 25 years ago
Working with an Agencyover 25 years ago
A Strategic Overview





